Search

Your search keyword '"Jarolim, Petr"' showing total 881 results

Search Constraints

Start Over You searched for: Author "Jarolim, Petr" Remove constraint Author: "Jarolim, Petr"
881 results on '"Jarolim, Petr"'

Search Results

1. Using regional sero-epidemiology SARS-CoV-2 anti-S antibodies in the Dominican Republic to inform targeted public health response

3. Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021-August 2022

5. Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies

7. Calibrating from Within: Multipoint Internal Calibration of a Quantitative Mass Spectrometric Assay of Serum Methotrexate

8. SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021

10. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

11. Convergence of SARS-CoV-2 Spike Antibody Levels to a Population Immune Setpoint

12. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

15. Abstract 10465: Abnormal Post Exercise Skeletal Muscle Microvascular Response and Metabolism Correlate With Patient Reported Outcomes in Patients With Intermittent Claudication From Peripheral Artery Disease

18. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response

19. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry

20. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells

21. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

24. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

25. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

31. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes

34. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

35. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL

36. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF

38. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58

39. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

44. Tracking immune correlates of protection for emerging SARS-CoV-2 variants

46. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome

47. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

Catalog

Books, media, physical & digital resources